drugset
drugset / Trial / NCT01894672

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672 ↗

Phase 2 Completed 7 enrolled Memorial Sloan Kettering Cancer Center Array BioPharma · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.

Timeline

Start
2013-07
Primary completion
2016-03-17
Completion
2016-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Encorafenib Small molecule 300 mg Oral

Indications

melanoma